These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 9432038

  • 1. A randomized phase II study of BB-10010: a variant of human macrophage inflammatory protein-1alpha for patients receiving high-dose etoposide and cyclophosphamide for malignant lymphoma and breast cancer.
    Bernstein SH, Eaves CJ, Herzig R, Fay J, Lynch J, Phillips GL, Christiansen N, Reece D, Ericson S, Stephan M, Kovalsky M, Hawkins K, Rasmussen H, Devos A, Herzig GP.
    Br J Haematol; 1997 Dec; 99(4):888-95. PubMed ID: 9432038
    [Abstract] [Full Text] [Related]

  • 2. A randomized phase-II study of BB-10010 (macrophage inflammatory protein- 1alpha) in patients with advanced breast cancer receiving 5-fluorouracil, adriamycin, and cyclophosphamide chemotherapy.
    Clemons MJ, Marshall E, Dürig J, Watanabe K, Howell A, Miles D, Earl H, Kiernan J, Griffiths A, Towlson K, DeTakats P, Testa NG, Dougal M, Hunter MG, Wood LM, Czaplewski LG, Millar A, Dexter TM, Lord BI.
    Blood; 1998 Sep 01; 92(5):1532-40. PubMed ID: 9716580
    [Abstract] [Full Text] [Related]

  • 3. Correlation of colony-forming cells, long-term culture initiating cells and CD34+ cells in apheresis products from patients mobilized for peripheral blood progenitors with different regimens.
    Bender JG, Lum L, Unverzagt KL, Lee W, Van Epps D, George S, Coon J, Ghalie R, McLeod B, Kaizer H.
    Bone Marrow Transplant; 1994 Apr 01; 13(4):479-85. PubMed ID: 7517260
    [Abstract] [Full Text] [Related]

  • 4. A phase II protection study of BB-10010 in patients with high grade non-Hodgkin's lymphoma undergoing intensive chemotherapy.
    Hough RE, Lorigan PC, Poynton C, Newland A, Gupta RK, Foran J, Hancock BW.
    Int J Oncol; 2003 Feb 01; 22(2):421-4. PubMed ID: 12527943
    [Abstract] [Full Text] [Related]

  • 5. Continuous infusion of macrophage inflammatory protein MIP-1alpha enhances leucocyte recovery and haemopoietic progenitor cell mobilization after cyclophosphamide.
    Marshall E, Woolford LB, Lord BI.
    Br J Cancer; 1997 Feb 01; 75(12):1715-20. PubMed ID: 9192972
    [Abstract] [Full Text] [Related]

  • 6. Transplantation potential of peripheral whole blood primed by VACOP-B chemotherapy plus filgrastim (r-metHuG-CSF) in patients with aggressive non-Hodgkin's lumphoma.
    Corato A, Ambrosetti A, Rossi B, Vincenzi C, Lambiase A, Perona G, Pizzolo G, de Wynter E, Nadali G.
    J Hematother Stem Cell Res; 2000 Oct 01; 9(5):673-82. PubMed ID: 11091491
    [Abstract] [Full Text] [Related]

  • 7. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR, Mangan KF, Glenn LD, Malaspina DR, Cropper T, Mullaney M, Macdonald JS.
    Bone Marrow Transplant; 1993 Oct 01; 12(4):337-45. PubMed ID: 7506091
    [Abstract] [Full Text] [Related]

  • 8. Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies.
    Long GD, Negrin RS, Hoyle CF, Kusnierz-Glaz CR, Schriber JR, Blume KG, Chao NJ.
    Cancer; 1995 Sep 01; 76(5):860-8. PubMed ID: 8625190
    [Abstract] [Full Text] [Related]

  • 9. Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer.
    Patrone F, Ballestrero A, Ferrando F, Brema F, Moraglio L, Valbonesi M, Basta P, Ghio R, Gobbi M, Sessarego M.
    J Clin Oncol; 1995 Apr 01; 13(4):840-6. PubMed ID: 7707109
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Myeloid progenitor cell proliferation and mobilization effects of BB10010, a genetically engineered variant of human macrophage inflammatory protein-1alpha, in a phase I clinical trial in patients with relapsed/refractory breast cancer.
    Broxmeyer HE, Orazi A, Hague NL, Sledge GW, Rasmussen H, Gordon MS.
    Blood Cells Mol Dis; 1998 Mar 01; 24(1):14-30. PubMed ID: 9516378
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma.
    Vaughan WP, Kris E, Vose J, Bierman PJ, Gwilt P, Armitage JO.
    J Clin Oncol; 1995 May 01; 13(5):1089-95. PubMed ID: 7738614
    [Abstract] [Full Text] [Related]

  • 17. Protective effects of BB-10010 treatment on chemotherapy-induced neutropenia in mice.
    Gilmore GL, DePasquale DK, Shadduck RK.
    Exp Hematol; 1999 Feb 01; 27(2):195-202. PubMed ID: 10029156
    [Abstract] [Full Text] [Related]

  • 18. A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma.
    Fontelonga A, Kelly AJ, MacKintosh FR, Hall S, Monroe P, Wilson GS, Shaft D, Ruthven A, Ascensao JL.
    Bone Marrow Transplant; 1997 May 01; 19(10):983-8. PubMed ID: 9169642
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.